How should a patient with chronic dry cough and no significant medical history be evaluated and managed?

Evaluation and Management of Chronic Dry Cough

Begin with a focused history screening for red flags, followed by a systematic evaluation for the four most common causes: upper airway cough syndrome (UACS), asthma, gastroesophageal reflux disease (GERD), and nonasthmatic eosinophilic bronchitis, using the duration-based algorithmic approach recommended by CHEST guidelines 1.

Initial Assessment: Red Flag Screening

First, immediately assess for life-threatening conditions that require urgent evaluation 1:

• Hemoptysis (any amount)
• Smokers >45 years with new or changed cough, or coexisting voice disturbance
• Adults 55-80 years with ≥30 pack-year smoking history (current or quit within 15 years)
• Prominent dyspnea at rest or night
• Hoarseness
• Systemic symptoms: fever, weight loss, peripheral edema with weight gain
• Swallowing difficulties with eating or drinking
• Vomiting
• Recurrent pneumonia
• Abnormal chest radiograph or respiratory exam

If any red flags are present, pursue immediate diagnostic workup including chest imaging before proceeding with the standard chronic cough algorithm.

Defining Chronic Cough

Chronic cough is defined as >8 weeks duration 1. This duration threshold is critical for narrowing your differential diagnosis and applying the appropriate management algorithm.

Initial Diagnostic Workup

For patients without red flags, obtain 2, 1:

• Chest radiograph (to exclude malignancy, infection, structural abnormalities)
• Spirometry (to assess for obstructive lung disease)
• Exhaled nitric oxide (if available, to assess for eosinophilic inflammation)
• Blood eosinophil count
• Validated cough severity assessment tool (to objectively measure treatment response)

Address High-Risk Medications and Exposures

Before extensive testing, discontinue 1:

• ACE inhibitors (if applicable) - wait 4-6 weeks to assess response
• Sitagliptin (DPP-4 inhibitor)
• Environmental and occupational exposures (identify and eliminate)
• Tobacco use (mandatory cessation)

The Four Most Common Causes (Account for ~90% of Cases)

1. Upper Airway Cough Syndrome (UACS)

• Previously called postnasal drip syndrome
• Look for: sensation of postnasal drip, throat clearing, nasal discharge, sinus pressure
• Empiric trial: First-generation antihistamine/decongestant combination or intranasal corticosteroids

2. Asthma/Cough-Variant Asthma

• May present without wheezing or dyspnea
• Spirometry may be normal at baseline
• Test for: Bronchial hyperresponsiveness (methacholine challenge if spirometry normal)
• Empiric trial: Inhaled corticosteroids ± bronchodilators

3. Gastroesophageal Reflux Disease (GERD)

• May be silent (no heartburn or regurgitation)
• Important caveat: Acid suppression alone (PPIs) is NOT recommended for cough treatment 1
• Consider comprehensive GERD management including lifestyle modifications and prokinetic agents if appropriate

4. Nonasthmatic Eosinophilic Bronchitis

• Normal spirometry and no bronchial hyperresponsiveness
• Elevated sputum eosinophils or exhaled nitric oxide
• Treatment: Inhaled corticosteroids

Empiric Treatment Strategy

Follow-up in 4-6 weeks after initiating treatment 1. Treat the most likely diagnosis based on clinical presentation. If initial treatment fails, sequentially address other common causes. Multiple conditions often coexist and may require combination therapy.

When Initial Evaluation Fails: Unexplained Chronic Cough

If cough persists >8 weeks after appropriate investigation and supervised therapeutic trials according to best-practice guidelines, this becomes unexplained chronic cough (UCC) 3.

Additional Testing for UCC

Objective testing should include 3:

• Bronchial hyperresponsiveness testing (if not already done)
• Eosinophilic bronchitis assessment (sputum eosinophils or exhaled nitric oxide)
• Consider therapeutic corticosteroid trial if testing unavailable

Treatment Options for Refractory UCC

The evidence-based treatment hierarchy for UCC:

1. Multimodality speech pathology therapy (Grade 2C recommendation) 3

   • First-line behavioral intervention
   • Cough suppression techniques
   • Improves cough severity and quality of life

2. Gabapentin (Grade 2C recommendation) 3

   • Dosing: Start 300 mg once daily, escalate as tolerated up to maximum 1,800 mg/day in two divided doses
   • Critical requirement: Discuss risk-benefit profile before initiation
   • Reassess risk-benefit at 6 months before continuing
   • Shown to improve quality of life in RCTs
   • Consider when quality of life is severely impacted

3. Low-dose morphine (preferred over gabapentin in some contexts) 2

   • Alternative neuromodulator for refractory cases

4. Pregabalin - Alternative to gabapentin 2

What NOT to Do in UCC

• Do NOT prescribe inhaled corticosteroids if bronchial hyperresponsiveness and eosinophilia tests are negative (Grade 2B) 3
• Do NOT prescribe PPI therapy if workup for acid GERD is negative (Grade 2C) 3

Referral Considerations

Refer to a specialized cough clinic when 1:

• Cough remains refractory after systematic evaluation and treatment
• Diagnostic uncertainty persists
• Quality of life is severely impaired despite treatment attempts

Key Clinical Pitfalls to Avoid

1. Incomplete investigation: Failing to systematically evaluate all four common causes leads to persistent "unexplained" cough that is actually undertreated
2. Premature use of neuromodulators: Gabapentin/pregabalin should only be used after proper diagnostic workup excludes treatable causes
3. PPI monotherapy for presumed GERD-related cough: This is ineffective and no longer recommended 1
4. Missing medication-induced cough: Always review ACE inhibitors and sitagliptin
5. Not using validated outcome measures: Objective cough assessment tools are essential for monitoring treatment response 1
6. Inadequate treatment duration: Allow 4-6 weeks for therapeutic trials before declaring treatment failure 1

Algorithm Summary

Step 1: Screen for red flags → If present, pursue urgent diagnostic workup

Step 2: Confirm chronic duration (>8 weeks), obtain CXR, spirometry, consider FeNO/eosinophils

Step 3: Eliminate ACE inhibitors, sitagliptin, environmental triggers, tobacco

Step 4: Empiric treatment for most likely cause(s) among the four common etiologies

Step 5: Reassess at 4-6 weeks; if improved, continue; if not, address alternative/additional causes

Step 6: If cough persists after systematic evaluation and treatment → Diagnose as UCC

Step 7: For UCC: Test for bronchial hyperresponsiveness and eosinophilia if not done

Step 8: For confirmed UCC: Speech pathology therapy ± gabapentin (with informed consent and 6-month reassessment)

Step 9: Consider referral to specialized cough clinic for refractory cases

This algorithmic approach maximizes diagnostic yield while avoiding unnecessary testing and ensures quality of life is prioritized through systematic, evidence-based management.